CClinicalTrials.gg
Sign In
Status unknownNCT05075174Updated Oct 12, 2021

Effect of Progesterone Levels on 15th Day After Embryo Transfer in Early Miscarriage < 7 WG or Evolving Pregancy Rates

An observational study in ART, sponsored by University Hospital, Montpellier. Status unknown at 1 site in France. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2021-10-12.

Sponsored by University Hospital, Montpellier · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
540
Ages
18 Years to 43 Years
Sex
Female
01

Study summary

Progesterone level has been studied at days before embryo transfert. But, progesterone blood level has not been studied 15 days after embryo transfert. The aim of this study is to study progesterone level impact at 15 days after embryo transfert on evolving pregnanies or early miscarriages.

02

Conditions studied

  • ART

Browse trials for

Keywords

  • betaHCG +
  • pregnancy development know
  • progesterone level
  • miscarriage
03

In context

Abortion, Spontaneous

320 studies on the registry are indexed under Abortion, Spontaneous; 53 are open to participants now.

This study's planned enrollment of 540 is above the median of 200 across 140 observational studies indexed under Abortion, Spontaneous.

Browse Abortion, Spontaneous studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

ART program in Montpellier hospital >18 years old Blood progesterone level 15 days after embryo transfert Pregnancy development know

Inclusion criteria

  • ART program in Montpellier hospital
  • age >18 years old
  • Blood progesterone level 15 days after embryo transfert
  • Pregnancy development know

Exclusion criteria

Exclusion criteria:

  • non uterine pregnancy
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
540 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. number of blood progesterone

    blood progesterone at day 15 after embryo transfert

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05075174
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
Oct 12, 2021
Start date
Nov 1, 2020
Primary completion
Sep 1, 2021
Completion
Jun 1, 2022 (estimated)
Last update
Oct 12, 2021

Study contacts

Noémie Ranisavljevic, M.D., Ph.D
Contact
n-ranisavljevic@chu-montpellier.fr
06 37 10 89 38 ext. 33
MARIE DUPORT PERCIER, assistante
Contact
m-duportpercier@chu-montpellier.fr
0467336427 ext. 33
Noémie Ranisavljevic, M.D., Ph.D
study director · University Hospital, Montpellier
MARIE DUPORT PERCIER
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Abortion, Spontaneous→

Other studies from this sponsor

University Hospital, Montpellier

Start the discussion